Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 134900
Corporate User License Price USD 6000
Corporate User License Price INR 404700
Site License Price USD 4000
Site License Price INR 269800
Request a Quote

Report Title

Acinetobacter Infections-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Acinetobacter Infections-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Acinetobacter Infections-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Acinetobacter Infections-Pipeline Review, H1 2017



Executive Summary

Acinetobacter Infections-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections-Pipeline Review, H1 2017, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape.

Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene and recent surgery or procedure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acinetobacter Infections-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acinetobacter Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acinetobacter Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 3, 28 and 16 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 8 molecules, respectively.

Acinetobacter Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Acinetobacter Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Acinetobacter Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Acinetobacter Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Acinetobacter Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Acinetobacter Infections (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Acinetobacter Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Acinetobacter Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Acinetobacter Infections-Overview 7

Acinetobacter Infections-Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 16

Acinetobacter Infections-Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Acinetobacter Infections-Companies Involved in Therapeutics Development 25

Achaogen Inc 25

Adenium Biotech ApS 25

Aridis Pharmaceuticals LLC 26

Atterx Biotherapeutics Inc 26

AvidBiotics Corp 27

Emergent BioSolutions Inc 27

Entasis Therapeutics Inc 28

Evaxion Biotech ApS 28

F. Hoffmann-La Roche Ltd 29

FOB Synthesis Inc 29

Hsiri Therapeutics LLC 30

LegoChem Biosciences Inc 30

Melinta Therapeutics Inc 31

Nosopharm SAS 31

Novabiotics Ltd 32

Omnia Molecular Ltd 32

Peptilogics Inc 33

Pfizer Inc 33

Redx Pharma Plc 34

Sarepta Therapeutics Inc 34

Sealife PHARMA GMBH 35

Shionogi & Co Ltd 35

Techulon Inc 36

Tetraphase Pharmaceuticals Inc 36

Vaxdyn SL 37

Xellia Pharmaceuticals ApS 37

Acinetobacter Infections-Drug Profiles 38

A-3APO-Drug Profile 38

AA-139-Drug Profile 40

AB-877-Drug Profile 41

Acinetobacter vaccine-Drug Profile 42

Antisense Oligonucleotide for Acinetobacter baumannii Infections-Drug Profile 43

Antisense Oligonucleotide for Acinetobacter baumannii Infections-Drug Profile 44

AR-401-Drug Profile 45

AvR2-V10-Drug Profile 46

CA-824-Drug Profile 48

cefiderocol-Drug Profile 49

CSA-13-Drug Profile 52

EBX-004-Drug Profile 54

ETX-2514 + sulbactam sodium-Drug Profile 55

EV-035-Drug Profile 57

FAB-001-Drug Profile 59

FSI-1671-Drug Profile 60

FSI-1686-Drug Profile 61

G-3KL-Drug Profile 62

GN-4474-Drug Profile 63

HT-06-Drug Profile 64

HT-07-Drug Profile 65

HT-10-Drug Profile 66

JSM-11-Drug Profile 67

LCB-100200-Drug Profile 68

MDN-0057-Drug Profile 69

Monoclonal Antibodies for Gram-Negative Bacterial Infections-Drug Profile 71

NOSO-95179-Drug Profile 72

NP-432-Drug Profile 73

Peptides for Infectious Diseases-Drug Profile 74

pneumonia vaccine-Drug Profile 75

RX-05-Drug Profile 76

RXP-873-Drug Profile 77

SLP-0901-Drug Profile 78

SLP-0905-Drug Profile 79

Small Molecule for Acinetobacter baumannii Infections-Drug Profile 80

Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections-Drug Profile 81

Small Molecule to Target Bacterial Cell Membrane for Acinetobacter Infections-Drug Profile 82

Small Molecules for Acinetobacter baumannii Infection-Drug Profile 83

Small Molecules for Bacterial and Fungal Infections-Drug Profile 84

Small Molecules for Bacterial Infections-Drug Profile 85

Small Molecules for Bacterial Infections-Drug Profile 86

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections-Drug Profile 87

Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections-Drug Profile 88

Small Molecules to Inhibit DNA Gyrase Subunit A and Topoisomerase IV for Gram-Negative Bacterial Infections-Drug Profile 89

Small Molecules to Inhibit LpxC for Gram Negative Bacterial Infections-Drug Profile 90

Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections and Respiratory Diseases-Drug Profile 91

Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections-Drug Profile 92

SPR-741-Drug Profile 93

Synthetic Peptide to Target Bacterial Cell Membrane for Gram Negative and Gram Positive Bacterial Infections-Drug Profile 96

Synthetic Peptides for Infectious Disease-Drug Profile 97

TN-5-Drug Profile 98

TP-6076-Drug Profile 99

VNRX-5113-Drug Profile 100

VXD-001-Drug Profile 101

VXD-003-Drug Profile 102

XEL-1001-Drug Profile 103

XEL-1002-Drug Profile 104

XEL-1003-Drug Profile 105

XEL-1007-Drug Profile 106

Acinetobacter Infections-Dormant Projects 107

Acinetobacter Infections-Product Development Milestones 109

Featured News & Press Releases 109

Appendix 114

Methodology 114

Coverage 114

Secondary Research 114

Primary Research 114

Expert Panel Validation 114

Contact Us 114

Disclaimer 115

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Acinetobacter Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Acinetobacter Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Acinetobacter Infections-Pipeline by Achaogen Inc, H1 2017

Acinetobacter Infections-Pipeline by Adenium Biotech ApS, H1 2017

Acinetobacter Infections-Pipeline by Aridis Pharmaceuticals LLC, H1 2017

Acinetobacter Infections-Pipeline by Atterx Biotherapeutics Inc, H1 2017

Acinetobacter Infections-Pipeline by AvidBiotics Corp, H1 2017

Acinetobacter Infections-Pipeline by Emergent BioSolutions Inc, H1 2017

Acinetobacter Infections-Pipeline by Entasis Therapeutics Inc, H1 2017

Acinetobacter Infections-Pipeline by Evaxion Biotech ApS, H1 2017

Acinetobacter Infections-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Acinetobacter Infections-Pipeline by FOB Synthesis Inc, H1 2017

Acinetobacter Infections-Pipeline by Hsiri Therapeutics LLC, H1 2017

Acinetobacter Infections-Pipeline by LegoChem Biosciences Inc, H1 2017

Acinetobacter Infections-Pipeline by Melinta Therapeutics Inc, H1 2017

Acinetobacter Infections-Pipeline by Nosopharm SAS, H1 2017

Acinetobacter Infections-Pipeline by Novabiotics Ltd, H1 2017

Acinetobacter Infections-Pipeline by Omnia Molecular Ltd, H1 2017

Acinetobacter Infections-Pipeline by Peptilogics Inc, H1 2017

Acinetobacter Infections-Pipeline by Pfizer Inc, H1 2017

Acinetobacter Infections-Pipeline by Redx Pharma Plc, H1 2017

Acinetobacter Infections-Pipeline by Sarepta Therapeutics Inc, H1 2017

Acinetobacter Infections-Pipeline by Sealife PHARMA GMBH, H1 2017

Acinetobacter Infections-Pipeline by Shionogi & Co Ltd, H1 2017

Acinetobacter Infections-Pipeline by Techulon Inc, H1 2017

Acinetobacter Infections-Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017

Acinetobacter Infections-Pipeline by Vaxdyn SL, H1 2017

Acinetobacter Infections-Pipeline by Xellia Pharmaceuticals ApS, H1 2017

Acinetobacter Infections-Dormant Projects, H1 2017

Acinetobacter Infections-Dormant Projects, H1 2017 (Contd..1), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Achaogen Inc, Adenium Biotech ApS, Aridis Pharmaceuticals LLC, Atterx Biotherapeutics Inc, AvidBiotics Corp, Emergent BioSolutions Inc, Entasis Therapeutics Inc, Evaxion Biotech ApS, F. Hoffmann-La Roche Ltd, FOB Synthesis Inc, Hsiri Therapeutics LLC, LegoChem Biosciences Inc, Melinta Therapeutics Inc, Nosopharm SAS, Novabiotics Ltd, Omnia Molecular Ltd, Peptilogics Inc, Pfizer Inc, Redx Pharma Plc, Sarepta Therapeutics Inc, Sealife PHARMA GMBH, Shionogi & Co Ltd, Techulon Inc, Tetraphase Pharmaceuticals Inc, Vaxdyn SL, Xellia Pharmaceuticals ApS

Acinetobacter Infections Therapeutic Products under Development, Key Players in Acinetobacter Infections Therapeutics, Acinetobacter Infections Pipeline Overview, Acinetobacter Infections Pipeline, Acinetobacter Infections Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand